# Lantern Pharma Inc.: overview LTRN · Nasdaq · CIK 1763950 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ltrn.md) · [Financials](/companies/ltrn/financials.md) · [Filings](/companies/ltrn/filings.md) · [Insiders](/companies/ltrn/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.42)](/filings/0001493152-25-021927.md) | not reported | [(0.42)](/filings/0001493152-26-023740.md) | [(0.40)](/filings/0001493152-26-037971.md) | [(0.39)](/filings/0001493152-25-021927.md) | not reported | [(0.30)](/filings/0001493152-26-023740.md) | [(0.57)](/filings/0001493152-26-037971.md) | | Free cash flow | $k | [(5,585) d](/filings/0001493152-25-021927.md) | [(3,975) d](/filings/0001493152-26-013612.md) | [(4,377)](/filings/0001493152-26-023740.md) | [(3,937) d](/filings/0001493152-26-037971.md) | [(4,573) d](/filings/0001493152-25-021927.md) | [(2,792) d](/filings/0001493152-26-013612.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.13)](/filings/0001213900-22-011581.md) | [(1.31)](/filings/0001493152-24-010302.md) | [(1.47)](/filings/0001641172-25-000926.md) | [(1.93)](/filings/0001493152-26-013612.md) | [(1.57)](/filings/0001493152-26-013612.md) | | Free cash flow | $m | [(10.6)](/filings/0001493152-23-008241.md) | [(12.8)](/filings/0001493152-24-010302.md) | [(14.4)](/filings/0001641172-25-000926.md) | [(17.8)](/filings/0001493152-26-013612.md) | [(15.7)](/filings/0001493152-26-013612.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ltrn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Empery Asset Management, LP](/funds/1469336.md) | 2026-06-30 | $3.5m | 842,669 | | New +842,669 | | [CM Management, LLC](/funds/1841857.md) | 2026-06-30 | $2.1m | 500,000 | | Added +250,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.8m | 425,118 | | Added +93,039 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.2m | 291,039 | | Added +175,039 | | [BIOS Capital Management, LP](/funds/1813845.md) | 2026-06-30 | $1.0m | 249,397 | | Reduced −615,038 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $428.9k | 102,819 | | Reduced −8,827 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $208.3k | 49,950 | | Added +343 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $199.7k | 47,895 | | New +47,895 | | [Westside Investment Management, Inc.](/funds/1538383.md) | 2026-06-30 | $199.5k | 47,850 | | Reduced −2,200 | | [Quadrature Capital Ltd](/funds/1651424.md) | 2026-06-30 | $165.1k | 39,593 | | New +39,593 | ## Recent filings [All 260 filings](/companies/ltrn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 20:15 ET | [DEF 14A](/filings/0001493152-26-047586.md) | Proxy statement, period 2026-10-19 | 0001493152-26-047586 | | 2026-10-01 | 20:01 ET | [8-K](/filings/0001493152-26-045344.md) | 3.01 Delisting notice | 0001493152-26-045344 | | 2026-09-30 | 20:05 ET | [8-K](/filings/0001493152-26-045100.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-045100 | | 2026-09-24 | 00:41 ET | [8-K](/filings/0001493152-26-044007.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-044007 | | 2026-09-23 | 11:45 ET | [8-K](/filings/0001493152-26-043808.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-043808 | | 2026-08-14 | 11:35 ET | [8-K](/filings/0001493152-26-037979.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-037979 | | 2026-08-14 | 11:30 ET | [10-Q](/filings/0001493152-26-037971.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037971 | | 2026-08-03 | 21:24 ET | [8-K](/filings/0001493152-26-035864.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-035864 | | 2026-06-12 | 20:30 ET | [S-1](/filings/0001493152-26-028460.md) | Registration statement | 0001493152-26-028460 | | 2026-06-02 | 23:40 ET | [8-K](/filings/0001493152-26-026696.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-026696 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013612.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1763950 - Tickers: LTRN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: TX - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.